Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
about
Interventions for skin reactions associated with targeted anticancer treatmentsInterventions for skin reactions associated with targeted anticancer treatmentsBrain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysisRelationship between EGFR expression, copy number and mutation in lung adenocarcinomasIn vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell.Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulatorsBiomarkers of oxidative stress and personalized treatment of pulmonary tuberculosis: emerging role of gamma-glutamyltransferase.The role of molecular analyses in the era of personalized therapy for advanced NSCLC.Whole genome expression analysis for biologic rational pathway modeling: application in cancer prognosis and therapy prediction.Predictors of lung cancer: noteworthy cell type differences.Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer.Non-small cell lung cancer: the era of targeted therapy.Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.Modulatory Effects of Curcumin and Tyrphostins (AG494 and AG1478) on Growth Regulation and Viability of LN229 Human Brain Cancer Cells.Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic α-aminophosphonates that act as novel topoisomerase II inhibitors.Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer.Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease.Simulating non-small cell lung cancer with a multiscale agent-based model.Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.Advances and Prospects in Cancer Immunotherapy
P2860
Q24187823-C58A4BC2-BC29-4816-BCC6-66B01316DCEEQ24235777-7FF37C0A-11BA-47DD-BE9C-87B378F68A61Q33433688-190ABC48-86C9-4C60-9DBA-E309922992C4Q33634703-781F2ADD-235B-4E64-A48C-CAFB0E8D9C33Q34588391-F1808409-689D-4D1B-A3D2-1A700D1EF031Q34627739-80665B5F-7A64-4E57-A3A2-6B48F4BC8480Q35960107-702E1188-F62E-46CE-986A-69459B64C6E1Q36111972-97BB2EB7-3D11-42DC-A3F3-84FBDB3AF4DAQ36615223-D2E8DAB9-920E-4C28-B92B-E9D6C0A65DC5Q36869938-BF26FEFF-CEEE-49A7-8FF0-D9980E9D49EEQ37238720-8E188021-3113-483E-816C-64FC319D67FDQ37603346-5871666B-5762-45B3-B3E4-E6022BB28FEFQ37619114-14E39A97-3321-45A4-9287-0125D96D9805Q37645231-FD7990C8-C826-4A2E-ACC7-E4ABC43A06F8Q38782479-44509BC5-CA8C-41CE-B85F-69B3FED59EDEQ38835764-434AC612-ED7C-4BDE-A1AE-FDC0312024FCQ38867098-1D6E056F-7D32-4601-BBF1-252453CF8418Q38933836-8640F823-B597-4984-BFB9-A3C29057D283Q39627560-BA76278F-89CB-4B99-A804-C7CC0F0944B3Q39683545-799376FE-B0B4-4078-AA4E-82CA09EE9F43Q42464328-352AF347-06AA-45E0-B865-2FECEAB01252Q42861436-78B49474-469F-40EA-8610-B73413AA8169Q54382849-D7572D3D-0527-46A0-BE49-2EABA261097DQ54494748-24AB83FA-39E7-4FF4-A204-BBBB6B82B102Q59072375-B1446432-21B5-47D1-8C05-283A2D1705DC
P2860
Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Targeted therapy for the treat ...... h factor receptor antagonists.
@ast
Targeted therapy for the treat ...... h factor receptor antagonists.
@en
type
label
Targeted therapy for the treat ...... h factor receptor antagonists.
@ast
Targeted therapy for the treat ...... h factor receptor antagonists.
@en
prefLabel
Targeted therapy for the treat ...... h factor receptor antagonists.
@ast
Targeted therapy for the treat ...... h factor receptor antagonists.
@en
P356
P1433
P1476
Targeted therapy for the treat ...... h factor receptor antagonists.
@en
P2093
Gerard A Silvestri
M Patricia Rivera
P304
P356
10.1378/CHEST.128.6.3975
P407
P577
2005-12-01T00:00:00Z